McKesson (NYSE:MCK) Issues Q2 2025 Earnings Guidance

McKesson (NYSE:MCK) issued an update on its second quarter 2025 earnings guidance on Friday morning. The company provided earnings per share guidance of 6.700-7.000 for the period, compared to the consensus earnings per share estimate of 7.240. The company issued revenue guidance of -.

Analysts Set New Price Targets

Several analysts recently issued reports on MCK shares. Barclays increased their target price on McKesson from $596.00 to $616.00 and gave the stock an overweight rating in a research report on Thursday, August 8th. Bank of America lifted their price objective on shares of McKesson from $590.00 to $670.00 and gave the company a buy rating in a research report on Tuesday, June 25th. Wells Fargo & Company upped their target price on shares of McKesson from $502.00 to $551.00 and gave the stock an equal weight rating in a research report on Thursday, May 9th. Mizuho lifted their price target on shares of McKesson from $540.00 to $570.00 and gave the company a neutral rating in a report on Thursday, August 8th. Finally, Leerink Partners dropped their price objective on shares of McKesson from $670.00 to $665.00 and set an outperform rating for the company in a report on Thursday. Two analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and an average price target of $624.93.

McKesson Stock Down 9.9 %

Shares of MCK opened at $514.75 on Friday. The business has a fifty day moving average of $576.35 and a 200 day moving average of $557.33. The company has a market cap of $66.88 billion, a PE ratio of 23.00, a P/E/G ratio of 1.29 and a beta of 0.44. McKesson has a 52-week low of $405.50 and a 52-week high of $637.51.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, August 7th. The company reported $7.88 EPS for the quarter, topping analysts’ consensus estimates of $7.21 by $0.67. McKesson had a net margin of 0.94% and a negative return on equity of 242.57%. The firm had revenue of $79.28 billion during the quarter, compared to analysts’ expectations of $82.53 billion. During the same period in the previous year, the company earned $7.27 EPS. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year. As a group, research analysts anticipate that McKesson will post 32.14 earnings per share for the current fiscal year.

McKesson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 1st. Investors of record on Monday, September 2nd will be paid a dividend of $0.71 per share. This is a positive change from McKesson’s previous quarterly dividend of $0.62. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date is Friday, August 30th. McKesson’s dividend payout ratio (DPR) is currently 12.69%.

Insider Activity at McKesson

In other news, EVP Leann B. Smith sold 600 shares of McKesson stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $585.53, for a total transaction of $351,318.00. Following the completion of the sale, the executive vice president now directly owns 2,022 shares in the company, valued at $1,183,941.66. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, EVP Leann B. Smith sold 600 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $585.53, for a total transaction of $351,318.00. Following the transaction, the executive vice president now directly owns 2,022 shares of the company’s stock, valued at $1,183,941.66. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Brian S. Tyler sold 3,753 shares of McKesson stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $626.03, for a total transaction of $2,349,490.59. Following the sale, the chief executive officer now directly owns 82,339 shares of the company’s stock, valued at approximately $51,546,684.17. The disclosure for this sale can be found here. Insiders sold a total of 8,106 shares of company stock worth $4,881,001 in the last quarter. 0.11% of the stock is owned by company insiders.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.